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AbstrACt
Objectives to compare responses in patients 
with early rheumatoid arthritis (rA) initially treated 
with the tumour necrosis factor inhibitor (tnFi) 
adalimumab+methotrexate (MtX) versus MtX 
monotherapy who may have continued receiving MtX or 
switched to adalimumab rescue therapy after inadequate 
response to MtX.
Methods optiMA enrolled MtX-naive patients 
with active rA for <1 year. this post hoc analysis 
determined the proportion of patients, stratified by 
initial treatment, who achieved 28-joint modified 
Disease Activity score based on C reactive protein 
<3.2, normal function and/or no radiographic 
progression at weeks 26, 52 and 78.
results significantly greater proportions of patients 
initially treated with adalimumab+MtX (n=466) 
compared with MtX monotherapy (n=460) achieved 
good clinical (53% vs 30%), functional (45% vs 33%) 
and radiographic (87% vs 72%) outcomes at week 
26. From weeks 26 to 78, adalimumab rescue patients 
achieved similar clinical and functional outcomes 
versus patients initially treated with adalimumab+MtX. 
However, significantly more patients initially treated with 
adalimumab+MtX had no radiographic progression at 
weeks 52 and 78 versus patients initially treated with 
MtX (both timepoints: 86% vs 72%).
Conclusions in early rA, starting with MtX 
monotherapy and adding tnFi after 26 weeks yields 
similar longer term clinical results as starting with 
tnFi+MtX combination therapy but allows a small but 
significant accrual of radiographic damage.
IntrOduCtIOn
The European League Against Rheumatism (EULAR) 
and American College of Rheumatology (ACR) 
recommend clinical remission or low disease activity 
(LDA) if remission is unlikely to be obtained, as 
the treatment goal for rheumatoid arthritis (RA).1 2 
Conventional synthetic disease-modifying antirheu-
matic drugs (DMARDs), particularly methotrexate 
(MTX), are recommended as part of an initial treat-
ment strategy. If disease activity has not improved at 
3 months, or the clinical target is not attained within 
6 months and the patient has unfavourable prog-
nostic markers, addition of a biological DMARD 
(bDMARD), such as a tumour necrosis factor inhib-
itor (TNFi), is recommended.1 2 
This analysis evaluated the treat-to-target 
strategy by assessing whether patients with early RA 
who started on MTX monotherapy, followed by 
addition of adalimumab on treatment failure, had a 
similar or worse outcomes compared with patients 
who started on adalimumab+MTX combination 
therapy.
MethOds
study design
OPTIMA was a 78-week, randomised, double-
blind, phase 4, two-period study.3 4 In period 1, 
patients received MTX monotherapy weekly or 
adalimumab 40 mg every other week plus MTX 
weekly for 26 weeks.3 The protocol defined stable 
LDA as 28-joint modified Disease Activity Score 
based on C reactive protein (DAS28(CRP)) <3.2 
at weeks 22 and 26. In period 2, patients with 
stable LDA continued MTX monotherapy or were 
rerandomised to adalimumab+MTX continuation 
or adalimumab withdrawal (MTX only).4 Patients 
who did not achieve stable LDA in period 1 
continued open-label MTX+adalimumab (adalim-
umab carry-on) or received open-label adalimumab 
added to MTX monotherapy (adalimumab rescue). 
All patients remained blinded to their initial treat-
ment allocation in period 1.4
Post hoc populations
A ‘merged adalimumab continuation’ group 
(including the ADA continuation arm, adjusted 
with a scaling factor based on the total number 
of patients in the adalimumab continuation and 
adalimumab withdrawal arms, so that both arms 
contributed equally) was combined with the 
adalimumab carry-on arm, comprising the total 
population randomised to adalimumab+MTX 
at baseline (online supplementary figure 1). The 
MTX monotherapy and adalimumab rescue arms 
were combined. These two main groupings allowed 
comparison of the validity of the EULAR and ACR 
recommendations of starting with MTX mono-
therapy followed by addition of a TNFi in patients 
who do not achieve the treatment target versus 
starting with TNFi+MTX.
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efficacy assessments
The main assessments were the proportion of patients who 
achieved DAS28(CRP) <3.2, normal function and no radio-
graphic progression at weeks 52 and 78. Normal function was 
defined as Disability Index of the Health Assessment Ques-
tionnaire (HAQ-DI) <0.5 and radiographic non-progression as 
change in modified total Sharp score (ΔmTSS) ≤0.5. We also 
assessed Boolean-based remission,5 Simplified Disease Activity 
Index (SDAI) remission (≤3.3), response rates for 20%/50%/70% 
improvements in ACR criteria and patient-reported outcomes 
(global assessment, pain, Functional Assessment of Chronic 
Illness Therapy and EuroQoL-5 dimensions).
statistical analyses
Outcomes were assessed using the last observation carried 
forward method, except radiographic analyses used multiple 
imputation (missing values imputed in 10 steps, Markov chain 
Monte Carlo method).6 Categorical outcomes were compared 
using the Pearson χ2 test4 and continuous outcomes using 
one-sample or two-sample t-tests.
results
As reported previously,3 a significantly greater proportion of patients 
receiving adalimumab+MTX, compared with those starting on 
MTX only, achieved LDA, normal function and radiographic 
non-progression at week 26. However, after therapy adjustment 
at week 26 in patients who failed to attain LDA, the proportions 
achieving LDA at weeks 52 and 78 and normal function were 
similar between the groups (figure 1A,B). Results were independent 
of glucocorticoid use (online supplementary figure 2). Moreover, 
the proportion of patients with radiographic non-progression (from 
week 0) remained stable from weeks 26 to 52 and 78, indicating that 
as soon as adalimumab rescue therapy began at week 26, progres-
sion of joint damage stopped (figure 1C). Likewise, the propor-
tion of patients with radiographic non-progression from week 26 
(‘reset’ baseline) to week 52 or 78 was similar between the groups 
(figure 1D). Moreover, the proportion of MTX monotherapy 
responders without radiographic progression at week 26 remained 
stable (ΔmTSS ≤0.5: 89/109 (81.7%) at week 52, 85/109 (78.0%) 
at week 78). Although significantly greater proportions of patients 
starting with adalimumab+MTX also achieved Boolean-based 
remission at weeks 26 and 52 and SDAI remission at week 26 versus 
Figure 1 Percentage of patients with clinical, functional and radiographic outcomes stratified by initial treatment regimen. (A) LDA based on 
DAS28(CRP) <3.2 at weeks 26, 52 and 78. (B) Normal function based on HAQ-DI <0.5 at weeks 26, 52 and 78. (C) Radiographic non-progression 
based on ΔmTSS ≤0.5 at weeks 26, 52 and 78. (D) Radiographic nonprogression based on ΔmTSS ≤0.5 from week 26 to 52 and from week 26 to 78. 
*This analysis group included the ADA continuation arm (n=105) and, after scaling to yield a proportional equivalent number of patients, the ADA 
withdrawal arm (n=102). †P<0.001, χ2 test. Missing DAS28(CRP) and HAQ-DI data were imputed using last observation carried forward; missing 
ΔmTSS data were imputed using multiple imputation. ADA, adalimumab; CRP, C reactive protein; DAS28, 28-joint modified Disease Activity Score; 
HAQ-DI, Disability Index of the Health Assessment Questionnaire; LDA, low disease activity; mTSS, modified total Sharp score; MTX, methotrexate;  
PBO, placebo.
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patients starting with MTX monotherapy, the differences were no 
longer significant subsequently (data not shown). Mean changes in 
clinical, functional and radiographic scores were significantly better 
in patients starting with adalimumab+MTX (P<0.001) from base-
line to week 26, whereas mean changes (except radiographic scores) 
were significantly better in patients starting with MTX mono-
therapy (P<0.001) from week 26 to weeks 52 and 78 (ie, after 
possible addition of adalimumab; data not shown). Mean changes 
in patient-reported outcomes from week 26 to weeks 52 and 78 
were similar in the two groups (data not shown).
ACR response rates from baseline to week 26 were higher on 
starting with adalimumab+MTX versus starting with MTX mono-
therapy, whereas in those starting with MTX monotherapy, the 
ACR rates were higher from week 26 to weeks 52 and 78 (figure 2). 
However, response rates were similar between groups from week 
52 to week 78 or baseline to week 78.
dIsCussIOn
This post hoc analysis of patients with early, active RA 
(disease duration: ~4 months3) compared 78-week outcomes 
in patients initially treated with MTX monotherapy, followed 
by addition of adalimumab if treatment target was not 
achieved, versus patients initially treated with adalimum-
ab+MTX combination therapy. Patients initially treated 
with MTX monotherapy had similar clinical, functional and 
patient-reported outcomes at weeks 52 and 78 as patients 
initially treated with adalimumab+MTX. Although initial 
adalimumab+MTX combination therapy resulted in mini-
mally superior radiographic outcomes at a group level 
compared with initial MTX monotherapy, these mean differ-
ences were not deemed clinically relevant because, per an 
established formula, this 1-point difference on the radio-
graphic scale translates to a negligible extent of irreversible 
functional impairment at the group level (0.01 HAQ points).7 
Also, patients starting with adalimumab+MTX had higher 
ACR response rates in period 1 than patients starting with 
MTX monotherapy, but this pattern was reversed at week 
52 when the baseline was ‘reset’ to week 26, so overall ACR 
response rates were similar by week 78. Thus, at a population 
level, starting with MTX monotherapy followed by addition 
of adalimumab in patients with early RA who did not respond 
to MTX within 6 months conveyed almost identical clinical, 
functional and quality of life (but not radiological) results at 
weeks 52 and/or 78 versus starting with adalimumab+MTX.
Figure 2 Response rates for patients achieving (A) 20%, (B) 50% and (C) 70% improvement in ACR criteria over the course of 78 weeks. *This 
analysis group included the ADA continuation arm (n=105) and, after scaling to yield a proportional equivalent number of patients, the ADA 
withdrawal arm (n=102). †Percentage improvement was assessed from week 26. ‡Percentage improvement was assessed from week 52. Missing 
data were imputed using last observation carried forward. ACR, American College of Rheumatology; ADA, adalimumab; MTX, methotrexate.
group.bmj.com on January 26, 2018 - Published by http://ard.bmj.com/Downloaded from 
292 Kavanaugh A, et al. Ann Rheum Dis 2018;77:289–292. doi:10.1136/annrheumdis-2017-211871
Clinical and epidemiological research
EULAR and ACR recommend starting with MTX monotherapy 
or MTX+glucocorticoids1 2 8 but not with a bDMARD+MTX, in 
all patients with RA. In patients who do not achieve a treatment 
target of at least LDA and who have unfavourable prognostic 
factors (as in OPTIMA), adding a bDMARD is recommended. Our 
data fully validate this treat-to-target strategy2 by showing that the 
overall population of patients starting on MTX monotherapy, over 
time, fared as well in clinical, functional and structural respects as 
those starting on adalimumab+MTX. Furthermore, among those 
starting on MTX monotherapy, 24% achieved stable LDA at week 
26,3 with little or no radiographic progression and mostly norma-
tive physical function thereafter; thus, the treat-to-target strategy 
allows for a good outcome without the need for a bDMARD, 
despite negative prognostic factors, and prevents overtreatment 
of one in four patients with active RA. Overall, by applying this 
strategy, approximately two of three patients with early RA achieve 
LDA or remission, the major therapeutic targets, within 1 year with 
essentially no or minimal joint damage.
To our knowledge, no previous study has addressed whether 
rapid addition of TNFi after MTX failure leads to different 
disease outcomes compared with an initial combination of 
TNFi+MTX. A further strength is the prospective design of this 
study. Limitations include the inherent bias of post hoc anal-
yses and that the target was defined a priori as DAS28(CRP) 
<3.2, rather than a more stringent response. Patients were also 
not allowed alterations in glucocorticoids as recommended in 
treatment guidelines.1 2 8 Additionally, all patients who failed 
to achieve a clinical target received adalimumab and MTX, 
without comparisons with other rescue treatment options (eg, 
triple DMARD therapy and another bDMARD). The adalim-
umab+MTX population was not treated-to-target, unlike the 
MTX monotherapy population, since no treatment adjustment 
was made in patients who did not achieve stable LDA with 
adalimumab+MTX at week 26. Nonetheless, many adalimu-
mab+MTX patients had further clinical/functional improve-
ments and maintained the halt of radiographic progression. 
Furthermore, treatment was switched to MTX monotherapy in 
a subset of patients starting with adalimumab+MTX who had 
LDA at weeks 22 and 26; no equivalent removal of a therapeutic 
component was allowed in patients starting with MTX mono-
therapy who achieved stable LDA. Finally, rescue therapy was 
open label, which could have biased patient responses, particu-
larly for the more subjective endpoints (eg, HAQ-DI); however, 
the initial treatment allocation remained blinded throughout the 
trial.
COnClusIOns
Consistent with current treatment recommendations, starting 
with MTX monotherapy and optimising treatment by adding 
adalimumab after treatment failure at 26 weeks allowed patients 
with early RA to achieve comparable long-term clinical, func-
tional and disease activity outcomes with patients who started 
with initial adalimumab+MTX combination therapy. This 
strategy also prevented potential overtreatment of approxi-
mately 25% of patients with early RA.
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